Pediatr. praxi. 2011;12(2):111-114

Fevers as the main disease manifestation

MUDr.Petra Król, doc.MUDr.Pavla Doležalová, CSc.
Klinika dětského a dorostového lékařství 1. LF UK a VFN v Praze

Fever belongs to the main disease manifestations in childhood. It is mainly a feature of infections, but also of a variety of inflammatory

and neoplastic disorders. Differential diagnosis of protracted or recurrent fever is often challenging. It is based on the meticulous directed

history, evaluation of clinical and laboratory findings during the fever episode as well as at afebrile interval. Periodic fever syndromes

are clinical entities within the broad spectrum of autoinflammatory disorders. They are characterised by disruption of innate immune

mechanisms. Recurrent fever episodes are accompanied with localised inflammatory manifestations. In majority they are connected

with mutations of genes involved in the regulation of inflammatory processes. According to the type of Mendelian inheritance they can

be divided into autosomal dominant: cryopyrin-associated periodic syndromes and TNF-receptor associated periodic syndrome, and

autosomal recessive: familiar Mediterranian fever and mevalonatekinase-associated periodic syndrome. PFAPA syndrome (Periodic Fever,

Aphtae, Pharyngitis, Adenitis) is a periodic syndrome without identifiable genetic cause. Periodic fever patients are treated according

to the severity of their individual phenotype and risk factors associated with the mutations involved.

Keywords: autoinflammatory, periodic fever, innate immunity, inflammation

Published: April 18, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Król P, Doležalová P. Fevers as the main disease manifestation. Pediatr. praxi. 2011;12(2):111-114.
Download citation

References

  1. Marshall GS, Edwards KM, Lawton AR. PFAPA syndrome. Pediatr Infect Dis J. 1989; 8(9): 658-659. Go to original source... Go to PubMed...
  2. Hofer M, et al. PFAPA (Periodic fever, aphtous stomatitis, pharyngitis and cervical adenitis) Syndrome registry: analysis of a cohort of 214 patients, in FMFSAID. Clin Exp Rheumatol 2008; 23(2): 273-274.
  3. Hofer MF, et al. International PFAPA syndrome registry: cohort of 214 patients. Pediatric Rheumatology 2008; 6(Suppl. 1): P182. Go to original source...
  4. Renko M, et al. A randomized, controlled trial of tonsillectomy in periodic fever, aphthous stomatitis, pharyngitis, and adenitis syndrome. J Pediatr, 2007; 151(3): 289-292. Go to original source... Go to PubMed...
  5. Licameli G, et al. Effect of adenotonsillectomy in PFAPA syndrome. Arch Otolaryngol Head Neck Surg, 2008; 134(2): 136-140. Go to original source... Go to PubMed...
  6. Hofer M, Cochard M, Anton J, et al. PFAPA (periodic fever, oral aphtae, pharyngitis and cervical adenitis) syndrome: a new consensus on diagnostic criteria. Ann Rheum Dis 2009; 68(Suppl. 3): 705.
  7. McDermott MF, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999; 97(1): 133-144. Go to original source... Go to PubMed...
  8. Drewe E, et al. Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and case study of anti-tumour necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor receptor associated periodic syndrome (TRAPS): clinical and laboratory findings in a series of seven patients. Rheumatology (Oxford) 2003; 42(2): 235-239. Go to original source... Go to PubMed...
  9. van der Meer JW, Radl J, van Nieuwkoop JA, et al. Hyperimmunoglobulinaemia D and periodic fever: a new syndrome. Lancet 1984; 19(1): 1087-1090. Go to original source... Go to PubMed...
  10. Drenth JP, et al. Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. International Hyper-IgD Study Group. Nat Genet 1999; 22(2): 178-181. Go to original source... Go to PubMed...
  11. Frenkel J, et al. Lack of isoprenoid products raises ex vivo interleukin-1beta secretion in hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum, 2002; 46(10): 2794-2803. Go to original source... Go to PubMed...
  12. Drenth JP, et al. Cutaneous manifestations and histologic findings in the hyperimmunoglobulinemia D syndrome. International Hyper IgD Study Group. Arch Dermatol, 1994; 130(1): 59-65. Go to original source... Go to PubMed...
  13. Drenth JP, Haagsma CJ, van der Meer JW. Hyperimmunoglobulinemia D and periodic fever syndrome. The clinical spectrum in a series of 50 patients. International Hyper-IgD Study Group. Medicine (Baltimore) 1994; 73(3): 133-144. Go to original source... Go to PubMed...
  14. Simon A, et al. Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Clin Pharmacol Ther, 2004; 75(5): 476-483. Go to original source... Go to PubMed...
  15. Takada K, et al. Favorable preliminary experience with etanercept in two patients with the hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum 2003; 48(9): 2645-2651. Go to original source... Go to PubMed...
  16. Arkwright PD, et al. Hyper IgD syndrome (HIDS) associated with in vitro evidence of defective monocyte TNFRSF1A shedding and partial response to TNF receptor blockade with etanercept. Clin Exp Immunol, 2002; 130(3): 484-488. Go to original source... Go to PubMed...
  17. Marchetti F, et al. Inefficacy of etanercept in a child with hyper-IgD syndrome and periodic fever. Clin Exp Rheumatol, 2004; 22(6): 791-792. Go to PubMed...
  18. Chae JJ, et al. Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to endotoxin and a defect in macrophage apoptosis. Mol Cell 2003; 11(3): 591-604. Go to original source... Go to PubMed...
  19. Chae JJ, et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc Natl Acad Sci U S A, 2006; 103(26): 9982-9987. Go to original source... Go to PubMed...
  20. Ozkaya N, Yalcinkaya F. Colchicine treatment in children with familial Mediterranean fever. Clin Rheumatol 2003; 22(4-5): 314-317. Go to original source... Go to PubMed...
  21. Livneh A, et al. Colchicine prevents kidney transplant amyloidosis in familial Mediterranean fever. Nephron 1992; 60(4): 418-422. Go to original source... Go to PubMed...
  22. Zemer D, et al. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med, 1986; 314(16): 1001-1005. Go to original source... Go to PubMed...
  23. Roldan R, et al. Anakinra: new therapeutic approach in children with Familial Mediterranean Fever resistant to colchicine. Joint Bone Spine 2008; 75(4): 504-505. Go to original source... Go to PubMed...
  24. Moser C, et al. Successful treatment of familial Mediterranean fever with Anakinra and outcome after renal transplantation. Nephrol Dial Transplant, 2009; 24(2): 676-678. Go to original source... Go to PubMed...
  25. Aksentijevich I, et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum 2002; 46(12): 3340-3348. Go to original source... Go to PubMed...
  26. Boschan C, et al. Neonatal-onset multisystem inflammatory disease (NOMID) due to a novel S331R mutation of the CIAS1 gene and response to interleukin-1 receptor antagonist treatment. Am J Med Genet A, 2006; 140(8): 883-886. Go to original source... Go to PubMed...
  27. Feldmann J, et al. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am J Hum Genet 2002; 71(1): 198-203. Go to original source... Go to PubMed...
  28. Prieur AM, et al. A chronic, infantile, neurological, cutaneous and articular (CINCA) syndrome. A specific entity analysed in 30 patients. Scand J Rheumatol Suppl, 1987; 66: 57-68. Go to original source... Go to PubMed...
  29. Hawkins PN, et al. Spectrum of clinical features in MuckleWells syndrome and response to anakinra. Arthritis Rheum 2004; 50(2): 607-612. Go to original source... Go to PubMed...
  30. Callejas JL, et al. Anakinra in mutation-negative CINCA syndrome. Clin Rheumatol, 2007; 26(4): 576-577. Go to original source... Go to PubMed...
  31. Hawkins PN, et al. Response to anakinra in a de novo case of neonatal-onset multisystem inflammatory disease. Arthritis Rheum 2004; 50(8): 2708-2709. Go to original source... Go to PubMed...




Pediatrics for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.